About: A Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic
Creator	Antinori-Lent, Kellie Drincic, Andjela Hirsch, Irl Korytkowski, Mary Mcdonnell, Marie Muniyappa, Ranganath Rushakoff, Robert
Source	Medline; PMC
abstract	The pandemic of COVID-19 has presented new challenges to hospital personnel providing care for infected patients with diabetes who represent more than 20% of critically ill patients in intensive care units. Appropriate glycemic management contributes to a reduction in adverse clinical outcomes in acute illness but also requires intensive patient interactions for bedside glucose monitoring, intravenous and subcutaneous insulin administration, as well as rapid intervention for hypoglycemia events. These tasks are required at a time when minimizing patient interactions is recommended as a way of avoiding prolonged exposure to COVID-19 by health care personnel who often practice in settings with limited supplies of personal protective equipment. The purpose of this manuscript is to provide guidance for clinicians for reconciling recommended standards of care for infected hospitalized patients with diabetes while also addressing the daily realities of an overwhelmed health care system in many areas of the country. The use of modified protocols for insulin administration, bedside glucose monitoring, and medications such as glucocorticoids and hydroxychloroquine that may affect glycemic control are discussed. Continuous glucose monitoring systems have been proposed as an option for reducing time spent with patients, but there are important issues that need to be addressed if these are used in hospitalized patients. On site and remote glucose management teams have potential to provide guidance in areas where there are shortages of personnel who have expertise in inpatient glycemic management.
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.1210/clinem/dgaa342
bibo:pmid	32498085
has license	no-cc
sha1sum (hex)	f4d3a7a68c569e27e15db858e76438d3af81eb1e
schema:url	https://doi.org/10.1210/clinem/dgaa342
resource representing a document's title	A Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic
has PubMed Central identifier	PMC7313952
has PubMed identifier	32498085
schema:publication	J Clin Endocrinol Metab
resource representing a document's body	covid:f4d3a7a68c569e27e15db858e76438d3af81eb1e#body_text
is schema:about of	covid:arg/f4d3a7a68c569e27e15db858e76438d3af81eb1e named entity 'critically ill patients' named entity 'intensive care units' named entity 'Inpatient' named entity 'diabetes' named entity 'critically ill patients' named entity 'hyperglycemia' named entity 'hypoglycemia' named entity 'blood glucose' named entity 'CSII' named entity 'outpatient setting' named entity 'diabetes' named entity 'COVID' named entity 'outpatient settings' named entity 'hypotension' named entity 'insulin therapy' named entity 'hydroxychloroquine' named entity 'sitagliptin' named entity 'Insulin' named entity 'SGLT2 inhibitors' named entity 'standard of care' named entity 'continuous glucose monitoring' named entity 'critically ill patients' named entity 'CSII' named entity 'insulin' named entity 'hyperglycemia' named entity 'insulin' named entity 'mg/dl' named entity 'e-consult' named entity 'secretagogue' named entity 'FDA' named entity 'insulin' named entity 'insulin resistance' named entity 'mg/dl' named entity 'hyperglycemia' named entity 'insulin' named entity 'diabetes care' named entity 'CSII' named entity 'FIO2' named entity 'hyperglycemia' named entity 'diabetic ketoacidosis' named entity 'COVID' named entity 'COVID-19' named entity 'personal protective equipment (PPE' named entity 'insulin therapy' named entity 'hypoglycemic reaction' named entity 'mmol/L' named entity 'diabetes management' named entity 'HbA1c' named entity 'cardiovascular' named entity 'antitussive' named entity 'Hydroxychloroquine' named entity 'liver function tests' named entity 'EMR' named entity 'infusion' named entity 'diabetes' named entity 'insulin' named entity 'hyperglycemia' named entity 'COVID-19' named entity 'catheter' named entity 'insulin therapy' named entity 'nasopharyngeal swab' named entity 'type 2 diabetes' named entity 'diabetes' named entity 'glucocorticoid' named entity 'morbidity' named entity 'glucose' named entity 'glargine' named entity 'insulin sensitivity' named entity 'diabetes' named entity 'COVID' named entity 'mmol' named entity 'hyperglycemia' named entity 'mechanical ventilation' named entity 'telemedicine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software